5,824 reports of this reaction
2.3% of all OMALIZUMAB reports
#9 most reported adverse reaction
FATIGUE is the #9 most commonly reported adverse reaction for OMALIZUMAB, manufactured by Genentech, Inc.. There are 5,824 FDA adverse event reports linking OMALIZUMAB to FATIGUE. This represents approximately 2.3% of all 248,573 adverse event reports for this drug.
OMALIZUMAB has an overall safety score of 78 out of 100. Patients taking OMALIZUMAB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for OMALIZUMAB, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for OMALIZUMAB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 5,824 FDA reports for OMALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.3% of all adverse event reports for OMALIZUMAB, making it a notable side effect.
If you experience fatigue while taking OMALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.